文献速递神经免疫

血浆置换对那他珠单抗相关进行性多灶性白质脑病无获益证据

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
PubMed 文献 · Neurology · 2017-02-22

该研究回顾性分析219例多发性硬化合并那他珠单抗相关进行性多灶性白质脑病(NTZ-PML)病例,其中184例(84%)接受血浆置换(PLEX)。单因素和多因素分析显示PLEX未降低死亡风险或改善临床结局,国家可预测死亡和不良结局,PML-IRIS发生预测不良结局。结论提示PLEX不应常规用于NTZ-PML。

要点

  • PLEX未改善NTZ-PML患者的生存或临床结局。
  • 国家与PML-IRIS发生是不良结局的预测因素。
  • 该研究证据等级为Class III,尚不能排除PLEX的重要获益或危害。

核心结论

  • PLEX未改善意大利或国际MS合并NTZ-PML患者的生存或临床结局,未来应谨慎使用。

研究设计与样本

  • 回顾性研究,检索医学文献纳入193例国际和34例意大利NTZ-PML病例,共分析219例。

主要发现

  • 184例(84%)接受PLEX,PLEX未降低死亡风险或不良结局的可能性。
  • 国家可预测死亡和不良结局,PML-IRIS发生可预测不良结局。

关键数值与推荐

  • 该研究提供Class III证据表明PLEX不改善NTZ-PML患者生存。
  • 研究缺乏统计精度以排除PLEX的重要获益或危害。

临床怎么用

  • 对NTZ-PML患者不应常规进行PLEX,需权衡利弊并谨慎决策。

局限性

  • 研究为回顾性设计,缺乏统计精度以排除PLEX的重要获益或危害。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)-associated progressive multifocal leukoencephalopathy (PML). METHODS: The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior immunosuppressant exposure, PML symptoms, PML lesion location at diagnosis, CSF JC virus status and copies, additional PML treatments and steroids, and PML immune reconstitution inflammatory syndrome (IRIS) development were investigated with both univariate and multivariate analyses. RESULTS: A total of 219 NTZ-PML cases were analyzed, and 184 (84%) underwent PLEX, which did not reduce the mortality risk or the likelihood of poor vs favorable outcomes. Country was predictive of mortality and poor outcome, while PML-IRIS development was predictive of poor outcome. CONCLUSIONS: PLEX did not improve the survival or clinical outcomes of Italian or international patients with MS and NTZ-PML, suggesting that this treatment should be performed cautiously in the future. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. The study lacks the statistical precision to exclude an important benefit or harm of PLEX.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Landi D, De Rossi N, Zagaglia S, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017. PMID: 28228569. doi:10.1212/WNL.0000000000003740

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。